Ketamine and Postoperative Depressive Symptom-PASSION

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03086148
Collaborator
(none)
84
1
2
16.5
5.1

Study Details

Study Description

Brief Summary

Perioperative depression symptom (PDS) is one of the common mental comorbidity, and influences the clinical outcomes and prognosis. However, there is no rapid acting treatment to deal with it during the limited hospital stay. This study aims to determine whether ketamine could improve the depressive symptom of peirioperative patients. It will also examine the safety for administrating ketamine as an antidepressant intraoperatively. Meanwhile, it will show if ketamine could improve anxiety, postoperative pain or delirium. This trial also will bring great concerns on patients with perioperative mental health and explore the measures to improve their psycho-related prognosis.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Low-dose Ketamine on Postoperative Depressive Symptom in Patients Undergoing Intracranial Tumor Resection (PASSION)
Actual Study Start Date :
Jul 5, 2017
Actual Primary Completion Date :
Aug 24, 2018
Actual Study Completion Date :
Nov 20, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: ketamine group

Drug: Ketamine
Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
Other Names:
  • Ketamine hydrochloride
  • Placebo Comparator: normal saline group

    Drug: Normal saline
    Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.

    Outcome Measures

    Primary Outcome Measures

    1. Response rate [Postoperative 3 days]

      ≥50% reduction in MADRS scores from baseline value.The MADRS is a 10-item tool, with scores ranging from 0 to 60, and determining the severity of depression.

    Secondary Outcome Measures

    1. The remission rate [Postoperative 3 days and discharge.]

      The remission rate is defined as the absolute value of MADRS no more than 10.

    2. Anxiety symptom [Postoperative 3 days.]

      The anxious symptom is defined as HADS score no less than 11.

    3. Postoperative delirium [Postoperative 1 day.]

      Postoperative delirium will be assessed by the Confusion Assessment Method for the Intensive Care Unit Scale (CAM-ICU) at 2 hours and 1 day after surgery.

    4. Severe pain [Postoperative 3 days.]

      The incidence of severe pain within first postoperative three days, which is defined as mean and peak numerical rating scale (NRS) are higher than 5.

    5. Postoperative 30-day quality of life reported by KPS [Postoperative 30 days]

      The quality of life will be evaluated by Karnofsky performance status (KPS) at postoperative 30 days.

    6. Psychiatric outcomes and complications [Postoperative 3 days and discharge.]

      Postoperative complications include psychiatric symptoms evaluated by Brief Psychiatric Rating Scale (BPRS), manic symptoms assessed through the 11-item Young Mania Rating Scale (YMRS), and dissociative symptoms measured by the Clinician Administered Dissociative States Scale (CADSS). Moreover, postoperative complications also include aphasia, epilepsy, hemorrhage.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Brain tumor located supratentorial area and need to receive elective craniotomy;

    2. Moderate to severe depressive symptom measured by the qualified psychiatric doctors.

    3. Ages between 18 and 65 years old.

    4. American Society of Anesthesiologists physical status I-III

    Exclusion Criteria:
    1. History of epilepsy;

    2. Major depression disorder patients undergoing antidepressive therapy within 2 weeks; 3 Psychiatric illness; 4 Drug abuse; 5 History of allergy to the research drug; 6 Tumor located in the Wernick area, Broca area or the frontal pole; 7 Hyperthyroidism; 8 Patients can not cooperate with investigators on psychiatric assessments; 9 Pregnant or breast-feeding woman; 10 refuse to sign inform consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beijing TianTan Hospital Beijing China 100070

    Sponsors and Collaborators

    • Beijing Tiantan Hospital

    Investigators

    • Study Chair: Ruquan Han, M.D., Ph.D, Department of Anesthesiology, Beijing Tiantan Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yuming Peng, Associate professor, Beijing Tiantan Hospital
    ClinicalTrials.gov Identifier:
    NCT03086148
    Other Study ID Numbers:
    • 2017-03-16
    First Posted:
    Mar 22, 2017
    Last Update Posted:
    Jul 7, 2020
    Last Verified:
    Jul 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 7, 2020